Board meeting outcome
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 1.1 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gayatri BioOrganics reported unaudited results for the quarter and half-year ended September 30, 2025. The company posted zero revenue from operations across both quarters and the full half-year, with total expenses of Rs. 21.13 lakhs in Q2 FY26 and Rs. 47.42 lakhs in H1 FY26, resulting in a net loss of Rs. 21.13 lakhs for the quarter and Rs. 47.42 lakhs for the half-year (versus Rs. 39.14 lakhs loss in H1 FY25). The balance sheet shows a deeply negative networth of Rs. (3,636.73) lakhs against equity share capital of Rs. 7,878.81 lakhs, with total borrowings of around Rs. 3,730 lakhs and total assets of just Rs. 167.01 lakhs. Operating cash flow remained negative at Rs. (38.36) lakhs. The company itself stated the financials are prepared on a going concern basis relying on a comfort letter from promoters, as it has no active business operations generating revenue.
This is a deeply distressed micro-cap situation for shareholders — zero operational revenue, widening losses, negative networth, and reliance on promoter support to stay afloat signal very high risk. The stock is unlikely to attract meaningful investor interest until the company resumes actual business operations or receives a substantial capital infusion.